9年积淀+本土硬数据！司美格鲁肽不只会减重，更在中国患者中打出护心价值

Core Viewpoint - The value of Semaglutide, a GLP-1 receptor agonist, has expanded beyond glucose control and weight loss to include cardiovascular outcomes, renal protection, metabolic remodeling, and long-term chronic disease management, particularly in the Chinese patient population [2][3]. Group 1: Chinese Chronic Disease Management - The burden of cardiovascular disease in China is significant, with stroke accounting for nearly 50% of cardiovascular deaths, a rate higher than in Western countries and East Asian neighbors [3]. - Chinese type 2 diabetes patients typically have a lower average BMI than Western populations but experience earlier and more pronounced beta-cell dysfunction [5]. Group 2: Cardiovascular Benefits - Semaglutide has demonstrated a 26% reduction in major adverse cardiovascular events (MACE) in the SUSTAIN 6 study, with an even greater reduction of 27% in Asian populations [6][8]. - The drug significantly reduces non-fatal stroke risk by 39%, addressing a critical clinical concern in China where stroke is a leading cause of cardiovascular mortality [7]. Group 3: Metabolic Management - In the SUSTAIN China study, Semaglutide treatment led to an average HbA1c reduction of 1.8%, with an 86.1% rate of patients achieving HbA1c below 7.0% [8][11]. - The drug also resulted in an average weight loss of 4.0 kg and a reduction in systolic blood pressure by 7.1 mmHg, indicating its comprehensive impact on metabolic health [11]. Group 4: Weight Loss Efficacy - In the STEP 7 study, Semaglutide 2.4 mg resulted in an average weight loss of 11.8% and a waist circumference reduction of 10.2 cm over 44 weeks, which is particularly significant for overweight and obese patients in China [12]. - The rising obesity rates in China, projected to reach 70.5% by 2030, highlight the importance of effective long-term management solutions like Semaglutide [12]. Group 5: Early Cardiovascular Benefits - The SELECT study showed that Semaglutide 2.4 mg reduced MACE risk by 20% in overweight or obese patients with cardiovascular disease, with a notable 41% reduction in MACE risk observed within just six months of treatment [13][14]. - These findings suggest that the cardiovascular benefits of Semaglutide may manifest even before significant weight loss occurs, indicating its potential for early intervention [13]. Group 6: Safety and Long-term Use - Semaglutide has a well-established safety profile, with the most common side effects being mild gastrointestinal issues that are manageable through established clinical practices [15]. - The drug's long-term usability is enhanced by physicians' familiarity with managing its side effects, which is crucial for chronic disease management [15]. Group 7: Evolving Standards in Chronic Disease Management - Semaglutide is evolving from a traditional diabetes and weight loss medication to a comprehensive tool for managing chronic diseases in China, supported by robust local evidence and clinical outcomes [16][18]. - The focus of chronic disease management is shifting towards early risk reduction and comprehensive metabolic control rather than solely on rapid glucose reduction or weight loss [18].